ProADM Biomarker Triage for Hospitalization Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for accurate and reliable means to determine whether patients with infectious disease symptoms require hospitalization, as current methods often lead to unnecessary hospital admissions due to cautious decision-making, straining healthcare resources and potentially missing patients who need intensive treatment.
Innovation Solution
A method using proADM or MR-proADM levels in patient samples to assess the risk of disease progression, with a cut-off value of 1.2 nmol/L ± 20% indicating the need for hospitalization, allowing primary healthcare providers to make informed decisions on treatment intensity and hospital admission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPs send patients to hospital based on clinical signs and symptoms alone, then patients who need intensive treatment are identified, but unnecessary hospital admissions increase causing strain on healthcare resources
Solution Approach 1:
The patent introduces proADM as an intermediary biomarker between clinical presentation and hospitalization decision. This mediator provides objective quantitative data that bridges the gap between cautious clinical judgment and resource-efficient triage, enabling more accurate risk stratification without relying solely on clinical signs and symptoms
Solution Approach 2:
The patent transforms the subjective assessment of clinical signs and symptoms into an objective quantitative parameter (proADM level). By measuring proADM concentrations and comparing them against established thresholds, the system converts qualitative clinical judgment into precise numerical data that directly informs hospitalization decisions, improving both reliability and resource efficiency
2Productivity
If GPs send fewer patients to hospital to reduce strain on resources, then healthcare resource efficiency improves, but patients who need intensive treatment may be missed
Solution Approach 1:
The proADM biomarker serves as a reliable intermediary that enables safe reduction of hospital admissions. By providing objective risk stratification, it allows GPs to confidently send home low-risk patients (those with proADM below threshold) while ensuring high-risk patients (those with proADM above threshold) receive appropriate hospital care, thus improving resource efficiency without compromising patient safety
Solution Approach 2:
The patent replaces the mechanical system of clinical observation and judgment with a biochemical measurement system. Instead of relying on subjective assessment of symptoms, the system uses laboratory measurement of proADM levels to objectively determine hospitalization need, enabling more accurate triage decisions that improve both resource efficiency and patient safety
3Reliability
If proADM testing is implemented to improve hospitalization decision accuracy, then unnecessary admissions are reduced, but additional testing time and resources are required
Solution Approach 1:
The patent implements proADM testing as a preliminary triage tool that is performed early in the patient encounter, before final hospitalization decisions are made. By obtaining proADM levels during the initial assessment phase rather than after deterioration, the system enables proactive risk stratification and appropriate patient routing, minimizing delays in care while improving decision accuracy
Data Source
AI summary
The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.